Asia Life Sciences Webinar Series 2023

Name: Asia Life Sciences Webinar Series 2023
Start: 2023-04-12T04:00:00Z
End: 2023-07-06T04:00:00Z

Please join us for a series of tailored webinars led by a cross-practice team of Morgan Lewis life sciences lawyers. The program focuses on hot topics, trends, and key developments in the life sciences industry essential to our clients and contacts operating in Asia.

This series includes bilingual sessions where we explore regional developments and updates.

Upcoming Sessions:

Piloting Through the Pathways of Employment Law: An Essential Guide for Emerging Companies
FDA’s New Guidance on Clinical Decision Support Software
Investing in Life Sciences Startups in the US – Key Issues and Considerations
US Government Enforcement: Recent Developments and Issues in Investigations
International Patent Portfolio Management Strategies for Asian Companies

Questions?

Please contact Bhavisha Arora, Summer Zhu, or Ai Isono.

Upcoming Events

13 June 2023 - US Government Enforcement: Recent Developments and Issues in Investigations
日本語中文(中国)

Join us for an overview of recent developments in US government enforcement, with a focus on corruption and fraud investigations. The US Department of Justice has shown increased interest in enforcing the Foreign Corrupt Practices Act in the life sciences sector.

Past Webinars and Recordings

06 June 2023 - Investing in Life Sciences Startups in the US – Key Issues and Considerations
Watch the presentation >> | View the slides >>

Join us for a presentation reviewing key issues and considerations investors in Asia should keep in mind when investing in startup companies in the US life sciences industry.
29 May 2023 - FDA’s New Guidance on Clinical Decision Support Software
日本語中文(中国)

Watch the presentation >> | View the slides >>

This webinar will provide an overview of the US Food and Drug Administration’s (FDA’s) long-awaited final guidance document for clinical decision support (CDS) software, explaining its interpretation of the CDS software exemption.
23 May 2023 - Piloting Through the Pathways of Employment Law: An Essential Guide for Emerging Companies
日本語中文(中国)

Watch the presentation >> | View the slides >> | Read the insight >>

Join us for a webinar on employment law issues affecting emerging life sciences companies. We will discuss the importance of confidentiality and invention assignment agreements, the risks of hiring independent contractors versus employees, post-termination restraint, classifications and overtime, and other issues you may face in Japan, China, and the United States.
17 May 2023 - US Patent Law in Life Sciences: Description and Enablement Requirement Developments
日本語中文(中国)

Watch the presentation >> | View the slides >>

Join us to discuss the newest developments in the written description of US patent law, seen in Juno Therapeutics, Inc. v. Kite Pharma, Inc.; developments in the enablement of US patent law, seen in Amgen Inc. vs. Sanofi; intertwining written descriptions and enablement; and how to draft claims of life science patent applications to meet both written descriptions and enablement.
08 May 2023 - Introduction to US Intellectual Property
日本語中文(中国)

Watch the presentation >> | View the slides (Bilingual) >>

Join us as we cover the basics of US intellectual property law—focusing on the scope and duration of patent protection—and discuss trade secret and patent licensing.
26 April 2023 - Considerations for Cross-Border Strategic Licenses and Collaborations for Asia-Based Life Sciences Companies
日本語中文(中国)

Watch the presentation >> | View the slides >> | Read the Insight >>

Join us for an overview of considerations and issues relevant to Asia-based companies entering cross-border strategic licenses and collaborations in the life sciences industry.
11 April 2023 - What Chinese Life Sciences Companies Need to Know Under US-China Tension
日本語中文(中国)

Read the Insight (in English) >> | Read the Insight (in Chinese) >>

Join us as we discuss how the Committee on Foreign Investment in the United States (CFIUS) reviews of Chinese investment in the US life sciences industries have attracted much stricter scrutiny following the recent CFIUS executive order from President Joseph Biden.

Sitemap